Global Health Resource Utilization and Cost-Effectiveness of Therapeutics and Diagnostics in Immune Thrombotic Thrombocytopenic Purpura (TTP)
In this review, we examine the current landscape of health resource utilization and cost-effectiveness data in the care of patient populations with immune thrombotic thrombocytopenic purpura. We focus on the therapeutic (therapeutic plasma exchange, glucocorticoids, rituximab, caplacizumab) and diag...
Main Authors: | Ayesha Butt, Cecily Allen, Adriana Purcell, Satoko Ito, George Goshua |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-07-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/12/15/4887 |
Similar Items
-
Hereditary Thrombotic Thrombocytopenic Purpura
by: Sanober Nusrat, et al.
Published: (2023-10-01) -
Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management
by: Senthil Sukumar, et al.
Published: (2021-02-01) -
Atypical Presentation of Thrombotic Thrombocytopenic Purpura without Hematological Features
by: Balraj Singh, et al.
Published: (2020-07-01) -
Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura - a case report and concise review of the literature
by: D Brodmann
Published: (2007-09-01) -
Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS‐13 activity and autoantibodies
by: Francesca Palandri, et al.
Published: (2021-12-01)